NCT01125501 is a NA clinical trial of Protandim in Metabolic Syndrome, sponsored by SomaLogic, Inc..

Who is sponsoring NCT01125501?

NCT01125501 is sponsored by SomaLogic, Inc..

What drugs are being tested in NCT01125501?

Interventions in NCT01125501: Protandim.

What condition does NCT01125501 study?

NCT01125501 studies Metabolic Syndrome.

Is NCT01125501 still recruiting?

NCT01125501 is currently withdrawn. Last updated 16 October 2017.

Last reviewed 2017-10-16 · How we verify

NCT01125501

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Protandim and the Metabolic Syndrome: A Preliminary Study to Define Protein Signatures That Change Along With Lowered Oxidative Stress Measured as F2 Isoprostanes or TBARS and Inflammation Measured as hsCRP

Withdrawn NA Last updated 16 October 2017

What this trial tests

NA trial testing Protandim in Metabolic Syndrome. Withdrawn.

Timeline

1 April 2010

Primary endpoint
1 June 2010

1 June 2010

Quick facts

Lead sponsor	SomaLogic, Inc.
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	prevention
Start date	1 April 2010
Primary completion	1 June 2010
Estimated completion	1 June 2010
Sites	1 location across United States

Drugs / interventions tested

Protandim — full drug profile →

Conditions studied

Metabolic Syndrome — all drugs for Metabolic Syndrome →

Sponsor

SomaLogic, Inc.

Who can join

Adults 40 to 60, any sex, with Metabolic Syndrome. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Measure Decrease in Oxidative Stress markers.
Time frame: every 30 days for 120 days
the primary purpose of this trial is a preliminary study to examine the relationship to markers of oxidative stress,in response to Protandim, in Metabolic Syndrome.

Sponsor's own description

Protandim will decrease markers of oxidative stress/inflammation in subjects with metabolic syndrome and proteomics will identify protein profiles that correlate with markers or/changes in oxidative stress.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging Vistas for the Nutraceutical <i>Withania somnifera</i> in Inflammaging.
Basudkar V, Gujrati G, Ajgaonkar S, Gandhi M, et al · · 2024 · cited 17× · PMID 38794167 · DOI 10.3390/ph17050597
Nitric oxide-inhibited chloride transport in cortical thick ascending limbs is reversed by 8-iso-prostaglandin-F2α.
Cabral PD, Silva GB, Baigorria ST, Juncos LI, et al · · 2022 · cited 1× · PMID 35977909 · DOI 10.23876/j.krcp.21.243

Verify or expand the search:

Other trials of Protandim

Trials testing the same drug.

NCT06429059 — ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) · Phase 2 · completed

Other recruiting trials for Metabolic Syndrome

Currently open trials in the same condition.

NCT07501858 — Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metaboli · recruiting
NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting

Other SomaLogic, Inc. trials

Trials by the same sponsor.

NCT03599531 — Utility of the SomaLogic Cardiovascular Disease (CVD) Secondary Risk Panel for Cardiovascular Risk · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01125501 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SomaLogic, Inc.
Last refreshed: 16 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01125501.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing